

=> d his

(FILE 'HOME' ENTERED AT 12:02:24 ON 14 MAY 2002)

FILE 'USPATFULL' ENTERED AT 12:02:34 ON 14 MAY 2002

L1	5447 S ?ESTRADIOL
	E LABRIE F/IN
L2	62 S E4
L3	59 S L1 AND L2
L4	562 S DEHYDROEPIANDROSTERONE
L5	38 S L3 AND L4
L6	26 S L5 AND MENOPAUS?
L7	26 S L6 NOT PY>=2000

L7 ANSWER 25 OF 26 USPATFULL

ACCESSION NUMBER: 91:92512 USPATFULL

TITLE: Combination therapy for selected sex steroid dependent cancers

INVENTOR(S): Labrie, Fernand, 2735 Boul. Ilgeois, Ste-Foy,
Quebec, Canada G1W 1Z9

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5064813		19911112
APPLICATION INFO.:	US 1989-413613		19891109 (7)
DISCLAIMER DATE:	20870421		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-146597, filed on 21 Jan 1988, now abandoned which is a continuation of Ser. No. US 1986-892214, filed on 31 Jul 1986, now patented, Pat. No. US 4760053		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	952		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 26 USPATFULL

IN Labrie, Fernand, Quebec, Canada

SUMM . . . Manni et al., Endocr. Rev. 7: 89-94; 1986). Beneficial effects of treatment with LHRH agonist have also been observed in post-menopausal women (Nicholson et al., J. Ster. Biochem. 23, 843-848, 1985).

DRWD . . . breast cancer. The following abbreviations are used: ER: estrogen receptor; AR: androgen receptor; PR: progesterone receptor;

GR:

glucocorticoid receptor; DHEAS: **dehydroepiandrosterone** sulfate; DHEA: **dehydroepiandrosterone**; .DELTA..sup.5 -diol androst-5-ene-3.beta.,17.beta.-diol; .DELTA..sup.4 -dione, androstenedione; E.sub.1 : estrone; E.sub.2 : 17.beta.-**estradiol**; T: testosterone; DHT: dihydrotestosterone; E.sub.2 S: E.sub.2 -sulfate; E.sub.1 -S; E.sub.1 sulfate; (1) LHRH-A; luteinizing hormone-releasing hormone agonist or antagonist; (2) ANTI-E: antiestrogen; (3) AND: androgen; (4) PROG: progesterin; (5) 17.beta.-HSD; inhibitor of 17.beta.-**estradiol** steroid dehydrogenase or 17.beta.-hydroxysteroid dehydrogenase; (6) ARO: inhibitor of aromatase activity; (7) 3.beta.-HSD: inhibitor of 3.beta.-hydroxysteroid, .DELTA..sup.5 -.DELTA..sup.4 isomerase; (8).

DETD . . . by the adrenals may be converted by a variety of biological pathways into estrogen. Among the estrogens thus produced are 17.beta.-**estradiol** and androst-5-ene-3.beta.,17.beta.-diol. It is therefore highly desirable to include an inhibitor of 17.beta.-**estradiol** dehydrogenase or 17.beta.-hydroxy steroid dehydrogenase. Such inhibitors close down the synthetic pathways

crossed

by vertical line 5 denoted "17.beta.-HSD" on.

DETD . . . of preventing ACTH from reaching the adrenals and thus of preventing the adrenals from synthesizing and secreting compounds such as **dehydroepiandrosterone** sulfate, a precursor of the synthesis of estrogen. Alternatively, inhibitors which close down synthetic pathways in the adrenals will achieve.

DETD . . . using active compounds described herein in accordance with the present invention. The concentrations of adrenal androgens and estrogens

such as **dehydroepiandrosterone** (DHEA), DHEA-S sulfate (DHEAS), androst-5-ene-3.beta.,17.beta.-diol (.DELTA.'-diol) and, the ovarian estrogen, 17.beta.-**estradiol** (E.sub.2) are measured by standard methods well known to those skilled in the art, see for example, F. Labrie et.

DETD Suitable antiestrogens which also include 7.alpha.-substituents of **estradiol** (European Pat. No. 0138504) and non-steroidal

L7 ANSWER 24 OF 26 USPATFULL

ACCESSION NUMBER: 94:97559 USPATFULL

TITLE: Methods of treating or preventing breast or
endometrial

cancer with low dose non-masculinizing androgenic
compounds

INVENTOR(S): Labrie, Fernand, Quebec, Canada

PATENT ASSIGNEE(S): Endorecherche, Inc., Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5362720		19941108
APPLICATION INFO.:	US 1993-15083		19930208 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-724532, filed on 28 Jun 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1452		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 20 OF 26 USPATFULL

ACCESSION NUMBER: 96:77760 USPATFULL

TITLE: Combination therapy for the treatment of
estrogen-sensitive disease

INVENTOR(S): Labrie, Fernand, Quebec, Canada

PATENT ASSIGNEE(S): Endorecherche Inc., Quebec, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5550107		19960827
APPLICATION INFO.:	US 1991-785890		19911104 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-321926, filed on 10 Mar 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jordan, Kimberly		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1665		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			


=> s e3

L1 1 LASOFOXIFENE/CN

=> d str cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-

OTHER NAMES:

CN **Lasofoxifene**

L3 ANSWER 5 OF 35 USPATFULL

ACCESSION NUMBER: 1999:22095 USPATFULL

TITLE: Therapeutic methods and delivery systems utilizing sex steroid precursors

INVENTOR(S): Labrie, Fernand, Quebec, Canada

PATENT ASSIGNEE(S): Endorecherche, Inc., Quebec, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5872114		19990216
APPLICATION INFO.:	US 1995-481668		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-180361, filed on 18 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-5619, filed on 19 Jan 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Cebulak, Mary C.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	1890		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sex steroid precursors such as **dehydroepiandrosterone** and **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal. . . ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of **menopause**. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the.

SUMM . . . to a method for preventing and/or treating vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, and **menopause** or contraception in susceptible warm-blooded animals including humans involving administration of **dehydroepiandrosterone** (DHEA), **dehydroepiandrosterone**-sulfate (DHEA-S) or compounds converted in vivo to either and to pharmaceutical products, including kits and pharmaceutical compositions for delivery of. . .

SUMM . . . 143:1700-1704, 1983). In agreement with such a role of androgens, urinary levels of androgen metabolites are lower in postmenopausal symptomatic **menopausis** than in matched controls and a significant decrease in conjugated **dehydroepiandrosterone** (DHEA) was found in the plasma of osteoporotic patients (Hollo and Feher, Acta Med. Hung. 20:133, 1964; Urist and Vincent,. . .

SUMM In one aspect, the invention provides a method for treating **menopause** comprising administering to a patient in need of such treatment an effective amount of at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, in combination with an effective amount of an estrogen,. . .

SUMM In another aspect, the invention provides a pharmaceutical composition for the treatment of **menopause** and other indications discussed herein comprising at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo

SUMM

sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, and at least one additional container having either a. . . .
. . . . pharmaceutical composition comprising a carrier having dissolved therein at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, said precursor being present at a concentration of at. . . . through said localized area of said skin or mucosa. The foregoing method is useful in treating the conditions discussed above, **menopausal** symptoms and other conditions which respond to replenishment of diminished DHEA levels, including but not limited to obesity, cardiovascular disease,. . . .

to either of the foregoing, and further comprising an estrogen or a progestin or. . .

SUMM In another aspect, the invention provides a kit for the treatment of **menopause** having a first container which includes at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, and at least one additional container having either a. . .

SUMM . . . pharmaceutical composition comprising a carrier having dissolved therein at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, said precursor being present at a concentration of at. . . localized area of said skin or mucosa. The foregoing method is useful in treating and/or preventing the conditions discussed above, **menopausal** symptoms and other conditions which respond to replenishment of diminished DHEA levels, including but not limited to obesity, cardiovascular disease,. . .

L3 ANSWER 6 OF 35 USPATFULL

ACCESSION NUMBER: 1999:7377 USPATFULL
 TITLE: Steroid sulphotase inhibitors
 INVENTOR(S): Reed, Michael John, London, United Kingdom
 Potter, Barry Victor Lloyd, Bath, United Kingdom
 PATENT ASSIGNEE(S): Imperial College of Science Technology & Medicine,
 London, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861390		19990119
APPLICATION INFO.:	US 1995-456122		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-196191, filed on 27 Dec 1994, now patented, Pat. No. US 5604215		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-18465	19910829
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Cook, Rebecca	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	681	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . sulphates, are known to play an important part as intermediates

in steroid metabolism in the human body. Oestrone sulphate and **dehydroepiandrosterone** (DHA) sulphate, for example, are known to play an important role as intermediates in the production, in the body, of. . . oestradiol. Oestrone sulphate, in particular, is known, for example, to represent one of the major circulating oestrogen precursors particularly in post-**menopausal** women and oestrone sulphotase activity in breast tumours is 100-1000 fold greater than that of other enzymes involved in oestrogen. . .

L3 ANSWER 1 OF 254 USPATFULL

ACCESSION NUMBER: 1998:162493 USPATFULL
TITLE: Therapeutic methods and delivery systems utilizing sex steroid precursors
INVENTOR(S): Labrie, Fernand, Quebec, Canada
PATENT ASSIGNEE(S): Endorecherche, Inc., Quebec, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5854229		19981229
APPLICATION INFO.:	US 1995-477173		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-180361, filed on 18 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-5619, filed on 19 Jan 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	1881		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . of PREMARIN per day per 50 kg of body weight when administered orally. In certain embodiments of the invention, the **estrogen** may be 17.beta.-**estradiol** administered percutaneously in a patch which is available from CIBA under the name ESTRADERM wherein the daily dose is between. . . .

DETD In each of the foregoing Examples 14-17, a progestin and/or an **estrogen** may be added. For example 0.005 to 0.02% 17 .beta.-**estradiol** and/or 0.2 to 2.0% medroxyprogesterone acetate may be added with corresponding reductions in water or ethanol or petrolatum. DHEA permeability. . . .

L3 ANSWER 2 OF 254 USPATFULL

ACCESSION NUMBER: 1998:162353 USPATFULL
TITLE: Enhanced chromatography using multiphoton detection
INVENTOR(S): Drukier, Andrzej K., Burke, VA, United States
Bielski, Roman, Coopersburg, PA, United States
PATENT ASSIGNEE(S): BioTraces, Inc., Fairfax, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5854084		19981229
APPLICATION INFO.:	US 1996-679671		19960712 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1129P	19950713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chin, Christopher L.	
ASSISTANT EXAMINER:	Nguyen, Bao-Thuy L.	
LEGAL REPRESENTATIVE:	Spencer & Frank	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)	

LINE COUNT: 2383

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . 1989. The high level of 2-hydroxyestrone is indicative of risk of osteoporosis. Therefore, the knowledge of the ratio of some **estrogen**, i.e. 17- β -**estradiol**, metabolites within the body is of tremendous importance. Moreover, steroid-related drugs are involved in social and ethical issues that include. . .

L3 ANSWER 3 OF 254 USPATFULL

ACCESSION NUMBER: 1998:150986 USPATFULL

TITLE: Sulfated benzothiophene derivatives, methods of use and

formulations containing same
INVENTOR(S): Clay, Michael Paul, Greenwood, IN, United States
Frolik, Charles Alan, Indianapolis, IN, United States
Jones, Charles David, Indianapolis, IN, United States
Lindstrom, Terry Donald, Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843984		19981201
APPLICATION INFO.:	US 1997-843308		19970414 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17110P	19960509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Ngo, Tamthom T.	
LEGAL REPRESENTATIVE:	Sales, James J., Boone, David E.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1200	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . alleviating the symptoms of post-menopausal syndrome, particularly osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. As used herein, the term "**estrogen**" includes steroidal compounds having estrogenic activity such as, for example, 17- β -**estradiol**, estrone, conjugated **estrogen** (Premarin.RTM.), equine **estrogen**, 17- β -ethynyl **estradiol**, and the like. As used herein, the term "progestin" includes compounds having progestational activity such as, for example, progesterone, norethynodrel, . . .

L3 ANSWER 4 OF 254 USPATFULL

ACCESSION NUMBER: 1998:150978 USPATFULL

TITLE: Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

INVENTOR(S): Bryant, Henry U., Indianapolis, IN, United States
Dodge, Jeffrey A., Indianapolis, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843976		19981201
APPLICATION INFO.:	US 1995-419230		19950410 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-330775, filed on 28 Oct 1994, now abandoned which is a division of Ser. No. US 1994-198456, filed on 18 Feb 1994, now patented, Pat. No. US 5407955		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	MacMillan, Keith D.		
LEGAL REPRESENTATIVE:	Strode, Janelle D., Boone, David E.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	728		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Data presented in Table 1 below shows comparative results among ovariectomized rats, rats treated with 17.alpha.-ethynyl **estradiol** (EE.sub.2 ; an orally available form of **estrogen**), and rats treated with a compound of the present invention (centochroman). Although EE.sub.2 caused a decrease in serum cholesterol when. . .

L3 ANSWER 7 OF 35 USPATFULL

ACCESSION NUMBER: 1999:7374 USPATFULL
TITLE: Controlled release systems and low dose androgens
INVENTOR(S): Labrie, Fernand, Quebec, Canada
Lepage, Martin, Quebec, Canada
PATENT ASSIGNEE(S): Endorecherche Inc., Quebec, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861387		19990119
APPLICATION INFO.:	US 1995-485762		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-398096, filed on 3 Mar 1995 which is a division of Ser. No. US 1992-900817, filed on 24 Jun 1992, now patented, Pat. No. US		

5434146

which is a continuation-in-part of Ser. No. US
1991-724532, filed on 28 Jun 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Ostrolenk, Faber, Gerb & Soffen, LLP
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . 1700-1704, 1983). In agreement with such a role of androgens,
urinary levels of androgen metabolites are lower in postmenopausal
symptomatic **menopausis** than in matched controls and a
significant decrease in conjugated **dehydroepiandrosterone**
(DHEA) was found in the plasma of osteoporotic patients (Hollo and
Feher, Acta Med. Hung. 20: 133, 1964; Urist and. . .

L3 ANSWER 17 OF 35 USPATFULL

ACCESSION NUMBER: 1998:82748 USPATFULL

TITLE: Therapeutic methods and delivery systems utilizing sex steroid precursors

INVENTOR(S): Labrie, Fernand, Quebec, Canada

PATENT ASSIGNEE(S): Endoreoherche, Inc., Quebec, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780460		19980714
APPLICATION INFO.:	US 1995-488392		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-5619, filed on 19 Jan 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Cebulak, Mary C.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1488		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sex steroid precursors such as **dehydroepiandrosterone** and **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment of vaginal atrophy, hypogonadism, . . . of collagen or connective tissues in the skin, and, in combination with an estrogen and/or progestin, for the treatment of **menopause**. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the. . .

SUMM This invention relates to a method for preventing and/or treating vaginal atrophy, hypogonadism, diminished libido and **menopause** in susceptible warm-blooded animals including humans involving administration of **dehydroepiandrosterone** (DHEA), **dehydroepiandrosterone**-sulfate (DHEA-S) or compounds converted in vivo to either and to pharmaceutical products for delivery of active ingredient(s) useful to the. . .

SUMM . . . 1700-1704, 1983). In agreement with such a role of androgens, urinary levels of androgen metabolites are lower in postmenopausal symptomatic **menopausis** than in matched controls and a significant decrease in conjugated **dehydroepiandrosterone** (DHEA) was found in the plasma of osteoporotic patients (Hollo and Feher, Acta Med. Hung. 20: 133, 1964; Urist and. . .

SUMM In one aspect, the invention provides a method for treating **menopause** comprising administering to a patient in need of such treatment an effective amount of at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, in combination with an effective amount of an estrogen, . . .

SUMM In another aspect, the invention provides a pharmaceutical composition for the treatment of **menopause** comprising at least one sex steroid precursor selected from the group consisting of **dehydroepiandrosterone**, **dehydroepiandrosterone** sulphate, and compounds converted in vivo to either of the foregoing, and further comprising an estrogen or a progestin or. . .

SUMM In another aspect, the invention provides a kit for the treatment of **menopause** having a first container which includes at least one